Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
J. Clin. Oncol 2020 Aug 06;[EPub Ahead of Print], AKS Salama, S Li, ER Macrae, JI Park, EP Mitchell, JA Zwiebel, HX Chen, RJ Gray, LM McShane, LV Rubinstein, D Patton, PM Williams, SR Hamilton, DK Armstrong, BA Conley, CL Arteaga, LN Harris, PJ O'Dwyer, AP Chen, KT FlahertyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.